Elsevier

Cytokine

Volume 12, Issue 9, September 2000, Pages 1385-1390
Cytokine

Short Communication
MODULATION OF CELL SURFACE MARKERS ON NK-LIKE T LYMPHOCYTES BY USING IL-2, IL-7 OR IL-12 IN VITRO STIMULATION

https://doi.org/10.1006/cyto.2000.0733Get rights and content

Abstract

Cytotoxicity and proliferation of NK-like T (CIK) cells are dependent on the continuous presence of exogenous cytokines, but it is not known which cytokine is optimal. Here, we compared the effect of exogenous interleukin 2 (IL-2), interleukin 7 (IL-7) or interleukin 12 (IL-12) on the generation of CIK cells in addition to IL-1, interferon-gamma and anti-CD3 antibodies. Cell surface markers important for cytotoxic activity and adhesion were defined and cytokines leading to their optimal expression were determined. The most important findings were: (a) IL-12 generates the most CD3/CD56-double-positive CIK cells, (b) the expression of LFA-1/CD11a which is important for cytotoxic activity is highest with IL-7, and (c) IL-7 also generates the most CD28-positive cells which may enhance T cell receptor co-stimulation. In summary, essential differences concerning antigen expression were found when generating CIK cells using IL-7 or IL-12 instead of IL-2. In particular, IL-12 may be of interest due to the high expansion of CD56 positive cells in CIK cell cultures and the important role of these cells in mediating cytotoxicity towards malignant tissues.

References (14)

There are more references available in the full text version of this article.

Cited by (37)

  • IL12 integrated into the CAR exodomain converts CD8<sup>+</sup> T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors

    2022, Molecular Therapy
    Citation Excerpt :

    Taken together, gene expression profiling implied a novel phenotype of NK-like T cells induced upon signaling through the IL12-CAR. The CD8+CD56+CD62Lhigh phenotype of IL12-CAR T cells resembled, although was not identical to, CIK cells,20,21 the recently described poly-functional NK cells,22 and anti-microbial cytotoxic T cells.23 CD94/NKG2A was highly upregulated in IL12-CAR T cells compared with conventional CAR T cells (Figure 4A).

  • Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway

    2016, Human Immunology
    Citation Excerpt :

    High variability in the range of CIK proliferation, from few to more than 1000 fold expansion, has been reported, suggesting that some patient/donor might be classified as “poor CIK expander” [13–15]. Considering that the recruitment of a sufficient number of immune cells capable to be specifically effective against tumor target cells is a crucial issue for adoptive immunotherapy, alternative strategies, based on additional soluble factors such as IL-1, IL-7, IL-12 or on allogeneic stimulation by irradiated PBMC, have been investigated to ameliorate both the number and the anti-tumor cytotoxic potential of CIK [16–18]. Moreover, immunotherapy approaches combining different immune effector cells have also been explored and, the association of DC, CTL and CIK have displayed encouraging results in the treatment of various malignant tumors [19].

  • A role for interleukin-12/23 in the maturation of human natural killer and CD56<sup>+</sup> T cells in vivo

    2008, Blood
    Citation Excerpt :

    CD56+ T cells thus have attributes of effector memory CD8 T cells, although the precise steps of differentiation of CD56+ T cells from naive CD8 T cells are still unknown. In vitro data have argued for a role for IL-12 in their development and/or expansion,52-55 but one report disputed the in vivo relevance of these findings for the pool of hepatic CD56+ T cells.55 We also previously showed that most CD56+ T cells constitutively express IL-12Rβ1.56

  • Adoptive cell therapies in thoracic malignancies

    2022, Cancer Immunology, Immunotherapy
View all citing articles on Scopus
f1

Correspondence to: Ingo G. H. Schmidt-Wolf, M.D., Medizinische Universitätsklinik und Poliklinik I, Sigmund-Freud-Str. 25, 53105 Bonn, Germany

View full text